Caribou Biosciences, Inc. (CRBU)

Market Cap	200.68M
Revenue (ttm)	9.12M
Net Income (ttm)	-164.26M
Shares Out	93.12M
EPS (ttm)	-1.79
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,370,908
Open	2.280
Previous Close	2.170
Day's Range	2.090 - 2.290
52-Week Range	0.660 - 3.535
Beta	2.59
Analysts	Strong Buy
Price Target	9.33 (+332.95%)
Earnings Date	Nov 7, 2025

About CRBU

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company’s lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus. It also develops CB-011, a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 23, 2021
• Employees: 147
• Stock Exchange: NASDAQ
• Ticker Symbol: CRBU
• Website: https://cariboubio.com

Financial Performance

In 2024, Caribou Biosciences's revenue was $9.99 million, a decrease of -71.01% compared to the previous year's $34.48 million. Losses were -$149.11 million, 46.1% more than in 2023.

Analyst Summary

According to 3 analysts, the average rating for CRBU stock is "Strong Buy." The 12-month stock price target is $9.33, which is an increase of 332.95% from the latest price.

Price Target

$9.33

(332.95% upside)

Analyst Consensus: Strong Buy